HIT Consultant April 3, 2024
What You Should Know:
– Nucleai, a pioneer in spatial AI biomarkers raises $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA.
– The investment brings Nucleai’s total funding to $60M and fuels their mission to transform personalized medicine through AI-powered patient selection for clinical trials.
AI-Driven Spatial Biomarkers
Nucleai’s groundbreaking technology deciphers the intricate conversations between cells within tissue samples. By leveraging AI and machine learning (ML), they translate this cellular dialogue into a dynamic “action plan” for pathologists. This empowers them to navigate complex diseases like cancer with unmatched precision, ultimately leading to better patient outcomes.
The new funding will propel Nucleai’s AI algorithms to the forefront of clinical trial design. Their approach...
Today's Sponsors
Today's Sponsor